REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - REGENXBIO is experiencing a transformational year, having a legacy of approximately 15 years in AAV gene therapy, initially focusing on out-licensing products like Zolgensma derived from its original intellectual property and technology [2] - In the last 8 to 10 years, the company has shifted towards developing new programs internally [2] Technology and Development - The company utilizes NAV technology, which includes over 100 vectors within the NAV family, and has five licensees primarily using AAV8 and AAV9 [3] - REGENXBIO has dosed over 5,000 patients with its technology over the years, indicating a significant level of experience and application in the field [3]